Neoadjuvant Fluzoparib in Germline BRCA-mutated Three-negative Breast Cancer Breast Cancer
Status:
Recruiting
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
Although many PARP inhibitors did not improve pCR in neoadjuvant studies, it is not an
unchallenged conclusion that TNBC does not benefit from use of PARP inhibitors in neoadjuvant
therapy.This study is an open-label, two-cohort, multicenter trial. 60 patients with germline
BRCA-mutated three-negative early breast cancer are planned to be enrolled and treated with
fluzoparib combined with chemotherapy according to tumor response after EC (epirubicin and
cyclophosphamide) for 2 cycles.
Phase:
Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University